Nasdaq
$1.38▲ 0.73%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $77.2MShares out 55.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
45- 10.21After-hours26.10.22 07:414Ownership#●●●
PDS Biotechnology Corp
PDS Biotechnology Corp (PDSB) insider John Andrew Dawson filed a Form 4 on October 21, 2026, reporting changes in beneficial ownership of securities as of October 18, 2026. This filing serves as the official disclosure of the executive's stock holdings adjustment to the SEC.…more
$1.38+0.73%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.21After-hours26.10.22 07:403Ownership
PDS Biotechnology Corp
John Andrew Dawson, an executive at PDS Biotechnology Corp, has filed a Form 3 to report his initial beneficial ownership of securities. This filing serves as the executive's initial statement of holdings.…more
$1.38+0.73%vs prev closeView filingShare - 10.21Overnight26.10.21 09:204Ownership
PDS Biotechnology Corp
Insider Deborah Ramsdell of PDS Biotechnology Corp reported a change in beneficial ownership of securities as of October 18, 2026. This filing serves as a standard Form 4 disclosure regarding the insider's equity holdings.…more
$1.38+0.73%vs prev closeView filingShare
44 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.20Pre-market26.10.20 21:00#●●●#●●●
PDS Biotechnology Appoints Three New Board Members
PDS Biotechnology has appointed three pharmaceutical industry veterans to its Board of Directors. This leadership change is intended to support the advancement of the company's PDS0301 Phase 3 clinical trial and its ongoing partnership strategies.…more
$1.38+0.73%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.6Pre-market26.10.06 21:00
●●●●●●●● ●●●●● ●●●●●●
PDS Biotechnology will host a virtual key opinion leader event to discuss clinical outcomes from the Phase 2 trial of PDS0301 for advanced colorectal cancer. The event aims to provide an overview of the drug's efficacy in patients with liver metastases.…more
$1.38+0.73%vs prev close - 9.22Pre-market26.09.22 21:00
●●●●●●●● ●●●●● ●●●●●●
PDS Biotech's Phase 2 clinical trial results for its HPV16-targeted immunotherapy PDS0101 in head and neck cancer have been published in JAMA Oncology. The company is currently pursuing a partnership strategy for PDS0101 while prioritizing the development of its colorectal cancer program.…more
$1.38+0.73%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report